In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17- demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 2, 2005, Pages 115-125

  Hollingshead, Melinda ^a   Alley, Michael ^a   Burger, Angelika M ^d   Borgel, Suzanne ^c   Pacula Cox, Christine ^a   Fiebig, Heinz Herbert ^b   Sausville, Edward A ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Institute for Experimental Oncology   (Germany)

^c SAIC FREDERICK INC   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

Ansamycin; Heat shock protein 90; Xenograft

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DIMETHYLAMINOETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; GELDANAMYCIN; NSC 707545; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BREAST CARCINOMA; CELL PROLIFERATION; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA; LUNG SMALL CELL CANCER; MELANOMA; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; XENOGRAFT;

ANIMALS; BENZOQUINONES; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; LACTAMS, MACROCYCLIC; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; MICE; MICE, NUDE; QUINONES; SKIN NEOPLASMS; SOLUBILITY; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 21244462689     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0939-2     Document Type: Article

References (34)

1. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Shoemaker RH, Mayo JG, Boyd MR (1988) Feasibility of drug screening with panels of human tumor lines using a microculture tetrazolium assay. Cancer Res 48:589-601
2. Alley MC, Pacula-Cox CM, Hollingshead, MG, Camalier RF, Mayo JG, Plowman, J, Malspeis L (1995) Utility of a PVDF filter plate assay to facilitate selection of tumor cell lines for in vivo drug testing. Proc Am Assoc Cancer Res 36:305
3. Banerji U, Clarke P, Walton M, O'Donnell A, Raynaud F, Turner A, Judson I, Workman P (2003) Preclinical and clinical activity of the molecular chaperone inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) in malignant melanoma (2nd edn) (abstract 2966). Proc Am Assoc Cancer Res 44:587
4. Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L (2003) Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res 9:4961-4971
5. Bonvini P, Gastaldi T, Falini B, Rosolen A (2002) Nucleophosmin- anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res 62:1559-1566
6. Burger (2001) Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int J Cancer 92:718-724
7. Burger AM, Fiebig HH, Stinson SF, Sausville EA (2004) 17-Allyl-amino-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15:377-387
8. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH (1970) Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 23:442-447
9. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL (1998) Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58:2385-2396
10. 1 mice and Fisher 344 rats. Cancer Chemother Pharmacol 49:7-19
11. Fiebig HH, Burger AM (2001) Human tumor xenografts and explants. In: Teicher BA (ed) Animal models in cancer research. Humana Press, Totowa, pp 113-137
12. Glaze ER, Lambert AL, Page J, Egorin M, Eiseman J, Holleran J, Tomaszewski JE (2003) Toxicity studies with 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin (17DMAG; NSC 707545). Clin Cancer Res [Suppl] 9:6215s
13. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR (1995) In vivo cultivation of tumor cells in hollow fibers. Life Sci 57:131-141
14. Hollingshead M, Plowman J, Alley M, Mayo J, Sausville E (1999) The hollow fiber assay. In: Fiebig HH, Burger AM (eds) Contributions to oncology, vol 54. Relevance of tumor models for anticancer drug development. Karger, Basel, pp 109-120
15. Jez JM, Chen JC, Rastelli G, Stroud RM, Santi DV (2003) Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. Chem Biol 10:361-368
16. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84:1424-1431
17. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature 425:407-410
18. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766
19. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088-1092
20. Nimmanapalli R, O'Bryan E, Bhalla K (2001) Geldanamycin and its analogue 17-allylamino-1-demethoxy geldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 61:1799-1804
21. Omura S, Iwai Y, Takahashi Y, Sadakane N, Nakagawa A, Oiwa H, Hasegawa Y, Ikai T (1979) Herbimycin, a new antibiotic produced by a strain of Streptomyces. J Antibiot (Tokyo) 32:255-261
22. Sausville EA, Tomaszewski JE, Ivy P (2003) Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 3:377-383
23. Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42:273-279
24. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM (2003) 17-DMA-geldanamycin is a novel water soluble orally bioavailable Hsp-90 inhibitor with potent in vitro and in vivo anti-cancer activity (2nd edn). Proc Am Assoc Cancer Res 44:153
25. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-993
26. Stancato LF, Silverstein AM, Owens-Grillo JK, Chow YH, Jove R, Pratt WB (1997) The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem 272:4013-4020
27. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89:239-250
28. Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305-315
29. Uehara Y, Hori M, Takeuchi T, Umezawa H (1985) Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn J Cancer Res 76:672-675
30. Uehara Y, Hori M, Takeuchi T, Umezawa H (1986) Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol 6:2198-2206
31. Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF (2000) The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60:342-349
32. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91:8324-8328
33. Xu L, Eiseman JL, Egorin MJ, D'Argenio DZ (2003) Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17- demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn 30:185-219
34. Xu W, Yuan X, Jung YJ, Yang Y, Basso A, Rosen N, Chung EJ, Trepel J, Neckers L (2003) The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res 63(22):7777-7784